2-165295879-G-A

Variant summary

Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BA1

This summary comes from the ClinGen Evidence Repository: The c.56G>A variant in SCN2A is a missense variant predicted to cause substitution of arginine by lysine at amino acid 19 (p.Arg19Lys). This variant is present at an allele frequency of 8% of the total population in gnomAD (v2.1.1), with the highest sub-population allele frequency in the East Asian population with an AF of 15%, which exceeds the threshold of 0.01% to meet the stand-alone criterion for Benign (BA1). This variant has not been reported in the literature to date in an individual with a complex neurodevelopmental disorder (PS2_not met, PM6_not met, PS4_not met). The variant has not been functionally characterized, and is not located in a pathogenic enriched region defined as a mutational hotspot (PM1_not met). In summary, this variant meets the criteria to be classified as BENIGN for AUTOSOMAL DOMINANT COMPLEX NEURODEVELOPMENTAL DISORDER based on the ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: BA1 (Epilepsy Sodium Channel VCEP specifications, version 1.0; approved 6/13/23). LINK:https://erepo.genome.network/evrepo/ui/classification/CA155062/MONDO:0100038/068

Frequency

Genomes: 𝑓 0.064 ( 359 hom., cov: 32)
Exomes 𝑓: 0.076 ( 4634 hom. )

Consequence

SCN2A
NM_001040142.2 missense

Scores

5
13

Clinical Significance

Benign reviewed by expert panel B:8

Conservation

PhyloP100: 2.48
Variant links:
Genes affected
SCN2A (HGNC:10588): (sodium voltage-gated channel alpha subunit 2) Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit with four repeat domains, each of which is composed of six membrane-spanning segments, and one or more regulatory beta subunits. Voltage-gated sodium channels function in the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel alpha subunit gene family. Allelic variants of this gene are associated with seizure disorders and autism spectrum disorder. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -8 ACMG points.

BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
SCN2ANM_001040142.2 linkuse as main transcriptc.56G>A p.Arg19Lys missense_variant 2/27 ENST00000375437.7 NP_001035232.1
SCN2ANM_001371246.1 linkuse as main transcriptc.56G>A p.Arg19Lys missense_variant 2/27 ENST00000631182.3 NP_001358175.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
SCN2AENST00000375437.7 linkuse as main transcriptc.56G>A p.Arg19Lys missense_variant 2/275 NM_001040142.2 ENSP00000364586 P1Q99250-1
SCN2AENST00000631182.3 linkuse as main transcriptc.56G>A p.Arg19Lys missense_variant 2/275 NM_001371246.1 ENSP00000486885 Q99250-2

Frequencies

GnomAD3 genomes
AF:
0.0638
AC:
9706
AN:
152150
Hom.:
358
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0296
Gnomad AMI
AF:
0.132
Gnomad AMR
AF:
0.0962
Gnomad ASJ
AF:
0.0652
Gnomad EAS
AF:
0.138
Gnomad SAS
AF:
0.126
Gnomad FIN
AF:
0.0381
Gnomad MID
AF:
0.0538
Gnomad NFE
AF:
0.0704
Gnomad OTH
AF:
0.0641
GnomAD3 exomes
AF:
0.0843
AC:
21148
AN:
250808
Hom.:
1097
AF XY:
0.0845
AC XY:
11453
AN XY:
135540
show subpopulations
Gnomad AFR exome
AF:
0.0297
Gnomad AMR exome
AF:
0.127
Gnomad ASJ exome
AF:
0.0620
Gnomad EAS exome
AF:
0.151
Gnomad SAS exome
AF:
0.121
Gnomad FIN exome
AF:
0.0424
Gnomad NFE exome
AF:
0.0694
Gnomad OTH exome
AF:
0.0700
GnomAD4 exome
AF:
0.0764
AC:
111622
AN:
1461794
Hom.:
4634
Cov.:
32
AF XY:
0.0776
AC XY:
56442
AN XY:
727194
show subpopulations
Gnomad4 AFR exome
AF:
0.0273
Gnomad4 AMR exome
AF:
0.120
Gnomad4 ASJ exome
AF:
0.0644
Gnomad4 EAS exome
AF:
0.0987
Gnomad4 SAS exome
AF:
0.116
Gnomad4 FIN exome
AF:
0.0452
Gnomad4 NFE exome
AF:
0.0741
Gnomad4 OTH exome
AF:
0.0743
GnomAD4 genome
AF:
0.0637
AC:
9706
AN:
152268
Hom.:
359
Cov.:
32
AF XY:
0.0645
AC XY:
4800
AN XY:
74456
show subpopulations
Gnomad4 AFR
AF:
0.0295
Gnomad4 AMR
AF:
0.0963
Gnomad4 ASJ
AF:
0.0652
Gnomad4 EAS
AF:
0.138
Gnomad4 SAS
AF:
0.126
Gnomad4 FIN
AF:
0.0381
Gnomad4 NFE
AF:
0.0704
Gnomad4 OTH
AF:
0.0639
Alfa
AF:
0.0697
Hom.:
770
Bravo
AF:
0.0666
TwinsUK
AF:
0.0698
AC:
259
ALSPAC
AF:
0.0820
AC:
316
ESP6500AA
AF:
0.0336
AC:
148
ESP6500EA
AF:
0.0716
AC:
616
ExAC
AF:
0.0818
AC:
9935
Asia WGS
AF:
0.114
AC:
397
AN:
3478
EpiCase
AF:
0.0700
EpiControl
AF:
0.0670

ClinVar

Significance: Benign
Submissions summary: Benign:8
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:2
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact Sciences-- -
Likely benign, no assertion criteria providedclinical testingGenetic Services Laboratory, University of Chicago-Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -
not provided Benign:2
Benign, criteria provided, single submitterclinical testingGeneDxMar 03, 2015- -
Benign, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitterclinical testingAmbry GeneticsJan 08, 2016This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Seizures, benign familial infantile, 3;C3150987:Developmental and epileptic encephalopathy, 11 Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
Seizures, benign familial infantile, 3 Benign:1
Benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaJan 12, 2018This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Complex neurodevelopmental disorder Benign:1
Benign, reviewed by expert panelcurationClinGen Epilepsy Sodium Channel Variant Curation Expert Panel, ClingenJun 13, 2023The c.56G>A variant in SCN2A is a missense variant predicted to cause substitution of arginine by lysine at amino acid 19 (p.Arg19Lys). This variant is present at an allele frequency of 8% of the total population in gnomAD (v2.1.1), with the highest sub-population allele frequency in the East Asian population with an AF of 15%, which exceeds the threshold of 0.01% to meet the stand-alone criterion for Benign (BA1). This variant has not been reported in the literature to date in an individual with a complex neurodevelopmental disorder (PS2_not met, PM6_not met, PS4_not met). The variant has not been functionally characterized, and is not located in a pathogenic enriched region defined as a mutational hotspot (PM1_not met). In summary, this variant meets the criteria to be classified as BENIGN for AUTOSOMAL DOMINANT COMPLEX NEURODEVELOPMENTAL DISORDER based on the ACMG/AMP criteria applied, as specified by the ClinGen Epilepsy Sodium Channel VCEP: BA1 (Epilepsy Sodium Channel VCEP specifications, version 1.0; approved 6/13/23). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.078
BayesDel_addAF
Benign
-0.38
T
BayesDel_noAF
Benign
-0.18
CADD
Pathogenic
33
DANN
Benign
0.96
DEOGEN2
Uncertain
0.50
.;T;.;.;T;T;.
Eigen
Benign
0.082
Eigen_PC
Uncertain
0.24
FATHMM_MKL
Uncertain
0.90
D
LIST_S2
Benign
0.74
T;T;.;.;.;.;T
MetaRNN
Benign
0.0015
T;T;T;T;T;T;T
MetaSVM
Benign
-0.46
T
MutationAssessor
Benign
1.8
.;L;L;L;L;L;L
MutationTaster
Benign
0.85
P;P;P;P
PrimateAI
Uncertain
0.67
T
PROVEAN
Benign
-1.3
N;N;.;.;.;N;N
REVEL
Uncertain
0.33
Sift
Benign
0.21
T;T;.;.;.;T;T
Sift4G
Benign
0.48
T;T;.;T;.;T;T
Polyphen
0.0010, 0.0020
.;B;B;B;B;B;B
Vest4
0.090, 0.062, 0.072, 0.088
ClinPred
0.011
T
GERP RS
5.5
Varity_R
0.38
gMVP
0.70

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.20
Details are displayed if max score is > 0.2
DS_AG_spliceai
0.20
Position offset: 2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs17183814; hg19: chr2-166152389; COSMIC: COSV51834563; API